In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript
Soumya Poddar(University of California, Los Angeles), Mike Mattie, Lei Huang, Jaeyeon Kim(Sidney Kimmel Cancer Center), Subing Cao, Tan Trinh(Aadi (United States)), Alessandro Calò, Madison Davis(Gilead Sciences (Australia)), Justin A. Budka(Gilead Sciences (United Kingdom)), Simone Filosto(Gilead Sciences (United States)), Chad M. Williams, Davide Bedognetti(Sidra Medical and Research Center), Rhine R. Shen(Broad Institute), Gabriela Balderrama-Gutierrez(University of California, Irvine), Q. David Walker, Jorge Andrade(University of Chicago), Stacey Valny, Sophie Viaud(Inserm)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
The Immune Landscape of Cancer
|Immunity|2019|806